**FLUID-BASED BIOMARKERS IN ALZHEIMER'S DISEASE: INSIGHT INTO DIAGNOSIS AND PROGRESSION**

Mumtaz Khan, Humair Ali

Jamia Hamdard- New Delhi-110062

**ABSTRACT**


Alzheimer's disease (AD) is a neurological ailment that causes cognitive decline and memory loss. Early and precise diagnosis of Alzheimer's disease is crucial for prompt intervention and better patient outcomes. Fluid-based biomarkers have emerged as useful tools for studying AD pathophysiology, assisting in early diagnosis, forecasting disease progression, and evaluating therapy success in recent years. This chapter presents an in-depth examination of fluid-based biomarkers in AD with an emphasis on cerebrospinal fluid (CSF), blood, and salivary indicators. We cover the most recent research findings on these biomarkers' diagnostic and prognostic usefulness, their potential as disease progression monitors, and their utility in assessing therapy response. The chapter focuses on the constraints and prospects of using fluid-based biomarkers to promote precise diagnosis of AD.

1. **INTRODUCTION**

AD is a complicated neurodegenerative condition of the brain that causes cognitive and behavioural symptoms. It is distinguished by the formation in the brain of two aberrant protein deposits: beta-amyloid plaques and tau tangles. Tau protein, which is normally found in healthy neurons, suffers aberrant modifications, forming twisted filaments that clump together to create tau tangles (Masters & Selkoe, 2012). These tangles interfere with neuron communication and contribute to cell malfunction and death. In contrast, beta-amyloid plaques are aberrant deposits of beta-amyloid protein fragments that form between nerve cells (J. Jin et al., 2021). These plaques disrupt neuronal function and are a defining feature of AD. The macroscopic pathology of AD is characterized by a considerable reduction in cortical size, with particularly noticeable abnormalities in the medial cortex (Masters & Selkoe, 2012; O’Brien & Wong, 2011). Affected brain regions show symptoms of inflammation, granulovacuolar degeneration, and the presence of peculiar structures known as Hirano bodies under a microscope. AD is a serious global health issue, affecting around 40 million people globally, and is expected to grow every 20 years until 2050 (Mayeux & Stern, 2012; Prince et al., 2016). In the United States, around 6 million people aged 65 and older have AD, with an estimated 500,000 new cases each year. The global prevalence of dementia among those aged 60 and up ranges from 2% to 8.5% (Prince et al., 2016). Despite substantial studies, effective Alzheimer's treatments remain elusive. One of the most difficult issues in AD research is the early and precise diagnosis of the condition because therapies are more likely to be beneficial if started early, while neuropathological alterations are modest (Klyucherev et al., 2022). Fluid-based biomarkers, such as CSF markers, blood-based markers, and developing salivary indicators, have the potential to improve AD understanding, aid in early diagnosis, monitor disease progression, and evaluate treatments. These biomarkers provide non-invasive and accessible methods for evaluating disease-related changes (Wen et al., 2021). This chapter seeks to provide a comprehensive review of significant fluid-based biomarkers in AD and investigate their roles in early diagnosis, disease monitoring, and therapy evaluation, as well as discuss obstacles and potential in improving precision in treatment (Mayeux & Stern, 2012).

1. **BIOMARKER**


Biomarkers are quantifiable compounds or indications present in biological samples like blood, urine, or tissue that can provide information about a biological process, condition, or illness (Strimbu & Tavel, 2010). A biomarker could be molecules, proteins, genetic material, and imaging features. Biomarkers have a wide range of uses in disease diagnosis, particularly in disease identification, characterization, and monitoring (Klyucherev et al., 2022). Biomarkers play an important role in clinical settings by assisting healthcare practitioners in making accurate and timely diagnoses. They give objective and quantitative measurements that aid in the differentiation of distinct diseases or subtypes, the assessment of disease severity, and the prediction of therapy response (Klyucherev et al., 2022; Strimbu & Tavel, 2010). Biomarkers allow for earlier disease detection, guiding appropriate therapeutic actions, and evaluating therapy efficacy. Their significance stems from their ability to increase diagnostic accuracy, improve patient care, and, ultimately, improve clinical results (Strimbu & Tavel, 2010).



**Fig1. The histopathological changes in AD. Senile plaques are composed of aggregated Aβ peptide, while neurofibrillary tangles consist of fibrillar deposits of p-Tau. neuroinflammation, synaptic dysfunction, and neurodegeneration.**

1. **FUNCTIONS OF BIOMARKERS**

Biomarkers play an essential role in medical research and clinical practice. They are employed in disease diagnostics, assisting healthcare experts in determining whether a specific disease or condition exists in an individual (Klyucherev et al., 2022). Biomarkers give useful diagnostic information, allowing for prompt and accurate diagnosis. Biomarkers influence disease prognosis. They can provide information about the likely course and prognosis of an illness, such as disease progression, severity, and responsiveness to treatment (Strimbu & Tavel, 2010). This information aids in therapy planning and patient management. Biomarkers play an important role in treatment selection and monitoring. They aid in the selection of the best treatment for a specific patient based on their biomarker profile. Biomarkers also help monitor the effectiveness of the chosen treatment, allowing adjustments to be made if needed (Klyucherev et al., 2022; Strimbu & Tavel, 2010)**.** Biomarkers are essential in the field of therapeutic development. They aid in the identification of potential pharmacological targets, the assessment of drug safety and effectiveness, and the monitoring of treatment effects during clinical trials(Simrén et al., 2021). Biomarkers are extremely important in the development of new therapies and medications. Biomarkers are also useful for r isk assessment, as they provide information about a person's likelihood of getting a specific disease or condition. This knowledge aids in the implementation of risk-mitigation measures and early intervention initiatives. Biomarkers, in general, serve an important role in improving healthcare outcomes and promoting medical research (Klyucherev et al., 2022).



**Fig 2. It shows the ATN (Amyloid, tau, neuroinflammation) system of classification of the biomarkers**

1. **FLUID BASED BIOMARKERS**

AD is an advancing neurodegenerative condition distinguished by a gradual deterioration of cognitive function and the loss of memory (Ferrer et al., 2005). The timely identification and precise diagnosis of AD are crucial to facilitate prompt intervention and enhance patient outcomes. In recent times, there has been a growing interest in the utilization of fluid-based biomarkers as potential diagnostic aids for AD (Papaliagkas et al., 2023). Fluid-based biomarkers, including CSF markers, blood-based markers, and arising salivary markers, have become increasingly important in the diagnosis of AD. In the context of CSF, certain biomarkers such as Aβ42, t-tau, and phosphorylated tau p-tau exhibit modified concentrations among individuals with AD, thereby facilitating the distinction between AD and other types of dementia (Engelborghs, 2013a). Blood-based biomarkers provide a readily available alternative for the diagnosis of AD, though with potentially lower sensitivity compared to cerebrospinal fluid CSF markers. In recent times, scholars have initiated investigations into salivary `alterations in the central nervous system (Gibbons et al., 2019). Although still in the preliminary stages of the investigation, salivary biomarkers such as Aβ42 and p-tau exhibit potential for future diagnostic applications in AD. In general, biomarkers based on fluid samples offer novel opportunities for early and precise diagnosis, potentially resulting in improved approaches for treatment and the overall management of this neurodegenerative disorder (Blennow & Zetterberg, 2018).

1. **CSF BIOMARKERS**
2. **CSF t- tau and p-tau**

The identification of biomarkers, namely t-tau and p-tau, in CSF provides significant implications for the diagnosis and comprehension of AD (Blennow et al., 2001; McGrowder et al., 2021). Elevated levels of t-tau have been regularly seen in individuals with MCI and those diagnosed with AD, in comparison to individuals who do not exhibit cognitive impairments (Engelborghs, 2013b). The detection of this increase is possible even during the initial phases of AD and exhibits a very consistent pattern over a period of time. Significantly, the levels of t-tau exhibit a strong correlation with memory function, rendering it a significant indicator in the evaluation of cognitive decline (Agnello et al., 2020; Engelborghs, 2013b).

In contrast, it has been observed that p-tau, a distinct variant of the tau protein, has markedly elevated concentrations in CSF among individuals diagnosed with AD in comparison to those who are deemed healthy (Blennow et al., 2001). The compelling aspect of p-tau lies in its robust correlation with the fundamental pathogenic mechanisms of AD, including the development of NFTs within the brain. In contrast to t-tau, which serves as an indicator of axonal damage, p-tau is more closely associated with the characteristic aspects of AD progression (Blennow, 2017; Mattsson-Carlgren et al., 2022). The association between p-tau and the pathophysiology of AD renders it a more dependable indicator for the early detection of the condition (Blennow & Zetterberg, 2018).

It is noteworthy that recent research has demonstrated that p-tau exhibits a superior discriminatory ability in distinguishing between individuals with AD and those without the condition, compared to t-tau, when evaluating diagnostic accuracy (Blennow & Zetterberg, 2018; Pyrgelis et al., 2022). Consequently, the utilization of CSF biomarkers, such as Aβ42 (associated with amyloid plaques), t-tau, and p-tau, presents a robust diagnostic instrument. The aforementioned combination demonstrates a sensitivity rate of 95% and a specificity rate of 83% in its ability to predict the onset of AD (Blennow et al., 2010; Frisoni et al., 2009; Hampel et al., 2004) Through the integration of these biomarkers, researchers and physicians are equipped with a comprehensive and precise set of tools to diagnose, monitor, and comprehend the advancement of AD (Gibbons et al., 2019).

1. **Aβ Peptides**

Aβ peptides play a critical role as CSF biomarkers in AD research, specifically indicating the presence of amyloid plaque accumulation in the brain (Blennow et al., 2001). Considerable research has been conducted on cerebrospinal fluid CSF Aβ peptides, specifically Aβ42, Aβ40, and the Aβ42/Aβ40 ratio, to explore their potential as biomarkers for AD (Blennow et al., 2001, 2010). Aβ peptides are generated through the proteolytic processing of the APP and constitute the principal constituents of amyloid plaques. Numerous studies haveconsistently provided evidence that a reduction in CSF levels of Aβ42 and an elevation in the Aβ42/Aβ40 ratio are closely linked to the accumulation of amyloid plaques in the brain, thus serving as strong indicators of AD pathology (Engelborghs, 2013a). Moreover, the integration of CSF Aβ42 measurements with tau biomarkers has demonstrated enhanced diagnostic precision, particularly during the initial phases of AD (Zou et al., 2020).

1. **Neurogranin (Ng)**

Ng is a protein located in the postsynaptic region of neurons, which is involved in the modulation of synaptic activity, plasticity, and long-term potentiation (LTP) through the regulation of calcium-mediated signaling pathways (Dulewicz et al., 2020). Synaptic impairment makes neurogranin a viable CSF biomarker for AD. Ng in the CSF indicates synaptic loss, making it a useful diagnostic for disease severity. It distinguishes AD from other dementias and predicts moderate cognitive MCI to AD (Sanfilippo et al., 2016). Ng exhibits a strong association with synaptic loss in individuals diagnosed with AD and its expression is predominantly observed in the cortex, hippocampus, and amygdala which are particularly susceptible to AD-related pathology. The levels of neurogranin in CSF exhibit an elevation in people diagnosed with MCI and AD in comparison to normal individuals (Öhrfelt et al., 2020). Combining Ng with established biomarkers like Aβ42, t-Tau, and p-tau improves diagnostic accuracy and sensitivity, helping diagnose early AD and measure therapy response (Dulewicz et al., 2020; Sanfilippo et al., 2016). Ng application is difficult since measurement needs sophisticated laboratory methods, limiting its clinical application. Defining normal and abnormal Ng levels is difficult due to the lack of established cutoff values and inter-laboratory heterogeneity.

1. **BLOOD-BASED BIOMARKERS**

Blood-based biomarkers present a potentially fruitful path for the identification of AD. In contrast to the study of CSF, blood tests provide the advantages of reproducibility, convenience, and reduced invasiveness, rendering them appropriate for extensive early identification and screening initiatives (Blennow, 2017). While blood-based biomarkers are generally considered to be less accurate than CSF indicators, current research endeavors to enhance their sensitivity and specificity in diagnosing AD (Frisoni et al., 2009). Prominent plasma proteins such as α2M, CFH, α1-antitrypsin, α1-antichymotrypsin, and Apolipoprotein A1 demonstrate modified expressions in individuals with AD in comparison to control subjects (Maes et al., 2006). However, the existence of obstacles remains due to the utilization of diverse analytical techniques, variations in anticoagulant selection, and discrepancies in storage settings (Hye et al., 2006). Extensive research has been conducted on plasma Aβ, a crucial constituent of cerebral plaques. The results of studies investigating the detection of plasma Aβ using enzyme-linked immunosorbent assay (ELISA) exhibit variability. Several studies have reported a modest elevation in Aβ42 or Aβ40 levels in patients with AD, however, other research has found no significant differences compared to control groups. It is worth noting that any alteration in the Aβ42/Aβ40 ratio may potentially serve as an indicator of AD risk (Maes et al., 2006).

Promisingly, a group of 18 plasma proteins effectively distinguished those with AD and anticipated the start of AD in those with MCI, suggesting the potential for preclinical diagnosis, but with the need for additional refinement (Blennow & Zetterberg, 2018; Zou et al., 2020). The integration of blood-based biomarkers with other methodologies has the potential to augment their precision and effectiveness in evaluating the risk and advancement of AD (Zou et al., 2020).

* 1. **Neurofilament Light Chain (NfL)**

NfL has emerged as a potentially valuable biomarker for AD research, as it has shown promise in detecting neurodegeneration and axonal damage using blood-based analysis. The presence of this substance in the bloodstream is indicative of the degeneration of neurons, facilitating the monitoring of the progression and severity of the sickness (Lin et al., 2018). The non-invasive nature of NfL has the potential to increase disease management and assessment of therapy response in the context of AD, hence offering the possibility of improved diagnosis and patient outcomes (M. Jin et al., 2019; Lee et al., 2022). Studies suggest higher NfL levels in individuals with AD, and these levels are associated with cognitive decline in both Alzheimer's and other neurodegenerative diseases (Giacomucci et al., 2022).

Plasma NFL may serve as a promising biomarker for cognitive decline. Although the potential of NfL is extensive, some problems need to be addressed (M. Jin et al., 2019). These challenges include the standardization of measuring techniques across different laboratories. However, additional longitudinal research is required to confirm its predictive capacity for the progression of dementia in patients with MCI and AD (Giacomucci et al., 2022; Lee et al., 2022).

* 1. **Plasma Aβ and Tau**

Blood-based assays have the potential to serve as substitutes for CSF biomarkers, as they can detect plasma levels of Aβ42, pTau181, and NfL using ultra-sensitive single-molecule array (Simoa) tests (Kivisäkk et al., 2023). AD patients can be distinguished through the measurement of the plasma Aβ42/Aβ40 ratio. However, it is important to note that the accuracy of this method is not as high as that of CSF testing (Simrén et al., 2021). There is a favorable association between blood t-tau levels and the likelihood of AD, indicating that blood t-tau levels can accurately predict tau-PET status across different cognitive stages (Lin et al., 2018; Smirnov et al., 2022). In the field of CSF analysis, the measurement of p-tau217 using the standard ELISA demonstrates superior performance compared to p-tau181 in predicting the status of Aβ and differentiating AD from other kinds of dementia (Lin et al., 2018). Additionally, plasma p-tau231 shows promising accuracy in discriminating between individuals with AD and individuals with non-AD. It is worth mentioning that the autoptic investigation of individuals with AD have demonstrated a discernible rise in plasma p-tau231 concentration before the increase observed in p-tau181 (M. Jin et al., 2019; Lin et al., 2018; Smirnov et al., 2022).

1. **SALIVARY BIOMARKERS**

Salivary biomarkers exhibit considerable potential for the detection of AD, albeit being in the nascent phases of development. Saliva, due to its non-invasive collection method and abundant presence of proteins, nucleic acids, and metabolites, presents itself as a promising diagnostic medium (Pekeles et al., 2019). It is worth mentioning that persons with AD display discernible variations in salivary levels of Aβ peptide, tau protein, and microRNA in comparison to those who are in good condition. Elevated levels of tau and Aβ42 in saliva have been linked to the presence of amyloid deposition and cognitive deterioration in individuals with AD (Song et al., 2018). The simplicity of collecting saliva enables frequent monitoring and facilitates longitudinal research, hence assisting in the assessment of therapy responses. Salivary biomarkers have the potential to distinguish AD from other neurodegenerative disorders, hence enhancing the precision of diagnostic procedures (Cao et al., 2019; Pekeles et al., 2019). The identification, validation, and standardization of salivary biomarkers present significant challenges, necessitating careful consideration of potential confounding factors such as nutrition, medication usage, and mouth health. Notwithstanding these challenges, the use of salivary biomarkers in standard AD diagnosis and care has the potential to improve individualized therapies by utilizing indicators of amyloid cascade and axonal injury to gain valuable knowledge (Pekeles et al., 2019).

Studies examining the salivary ratio of p-tau to t-tau, levels of α-synuclein, and the neuroprotective mediator heme oxygenase-1 have yielded significant findings. However, the practical application of these findings in therapeutic settings has not been fully achieved at now (Ferrer et al., 2005).

1. **URINARY BIOMARKERS**

Urine is a highly valuable biofluid that can be effectively employed as a viable source of biomarkers to diagnose neurodegenerative disorders (Yao et al., 2018). Nevertheless, urine has traditionally been considered an unsuitable biomarker for neurodegenerative illnesses due to its anatomical distance from the CNS, which is a primary site of pathology for these diseases. This sets it apart from other biofluids such as CSF and plasma (Wang et al., 2022; Yao et al., 2018). Recent research has presented a counterargument to this prevailing belief, suggesting that urine may possess untapped potential when analyzed using metabolomic and proteomic methodologies. Although osteopontin, gelsolin, and insulin-like growth factor-binding protein 7 have been identified in the urine of individuals with AD in early studies, there is still a hurdle in obtaining the desired level of specificity and sensitivity (Jiang et al., 2022). It is worth mentioning that the hyperphosphorylation of tau, which plays a crucial role in the development of AD, has been detected in the urine exosomes of individuals affected by this condition (Koyner et al., 2010). The potential of technological developments in urine analysis to facilitate the identification of new biomarkers is significant, as it allows for the full characterization of RNA, gene, protein, and metabolite components (Seol et al., 2020). Certain biomarkers, such as urine formaldehyde and 8-OHdG, exhibit a correlation with the severity of diseases, hence suggesting their potential as predictive indicators (Seol et al., 2020). However, it is important to conduct independent validation to establish their reliability and accuracy. As scientific investigations progress, the previously overlooked potential of urine as a valuable reservoir of biomarkers for neurodegenerative diseases becomes more evident (Jiang et al., 2022; Koyner et al., 2010; Seol et al., 2020).

**V. CONCLUSION**

Over the last two decades, fluid-based biomarkers for AD have shown promise for early diagnosis, disease-specific therapy, and disease monitoring, even without disease-modifying medications. This progress shows the importance of fluid-based biomarkers like CSF, blood, and salivary indicators in AD research and treatment. These biomarkers have transformed our understanding of AD biology, enabling accurate and early diagnosis, disease progression tracking, and treatment evaluation. The combination of non-invasive, cost-effective blood analysis with biomarkers improves diagnosis accuracy and longitudinal biologic monitoring. Emerging non-amyloid CSF or blood biomarkers may be next-generation AD indicators, although they need more validation. Using blood-based biomarkers for clinical application could lead to advancements in diagnosis and therapy. Amyloid or tau-based techniques can improve diagnosis and lead to new treatments. These novel biomarkers help design tailored AD treatments and disease-modifying approaches. With improved analytical capabilities, biomarker research can drive more efficient clinical trials and optimize biomarker-guided techniques, resulting in their seamless incorporation into AD diagnosis and care in clinical practice. Future biomarker profiles, precision-guided medications, and a better knowledge of AD's complex terrain promise a new era in individualized AD therapy.

**REFERENCES**

.

1. Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Lo Sasso, B., Iacolino, G., Giglio, V. R., Lupo, F., Alongi, P., Bivona, G., & Ciaccio, M. (2020). Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. *Scandinavian Journal of Clinical and Laboratory Investigation*, *80*(4), 313–317. <https://doi.org/10.1080/00365513.2020.1740939>
2. Blennow, K. (2017). A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood. In *Neurology and Therapy* (Vol. 6). <https://doi.org/10.1007/s40120-017-0073-9>
3. Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer's disease. In *Nature Reviews Neurology* (Vol. 6, Issue 3). <https://doi.org/10.1038/nrneurol.2010.4>
4. Blennow, K., Vanmechelen, E., & Hampel, H. (2001). CSF total tau, Aβ42, and phosphorylated tau protein as biomarkers for Alzheimer’s disease. *Molecular Neurobiology*, *24*(1–3). <https://doi.org/10.1385/MN:24:1-3:087>
5. Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer’s disease: current status and prospects for the future. In *Journal of Internal Medicine* (Vol. 284, Issue 6). <https://doi.org/10.1111/joim.12816>
6. Cao, Z., Wu, Y., Liu, G., Jiang, Y., Wang, X., Wang, Z., Zhang, J., & Feng, T. (2019). α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. *Neuroscience Letters*, *696*. <https://doi.org/10.1016/j.neulet.2018.12.030>
7. Dulewicz, M., Kulczyńska-przybik, A., & Mroczko, B. (2020). Neurogranin and VILIP-1 as molecular indicators of neurodegeneration in Alzheimer’s disease: A systematic review and meta-analysis. In *International Journal of Molecular Sciences* (Vol. 21, Issue 21). <https://doi.org/10.3390/ijms21218335>
8. Engelborghs, S. (2013a). CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives. *Journal of Neurological Disorders*, *01*(01). <https://doi.org/10.4172/2329-6895.1000e102>
9. Engelborghs, S. (2013b). CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives. *Journal of Neurological Disorders*, *01*(01). <https://doi.org/10.4172/2329-6895.1000E102>
10. Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005). Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies. *Current Alzheimer Research*, *2*(1), 3–18. <https://doi.org/10.2174/1567205052772713>
11. Frisoni, G. B., Prestia, A., Zanetti, O., Galluzzi, S., Romano, M., Cotelli, M., Gennarelli, M., Binetti, G., Bocchio, L., Paghera, B., Amicucci, G., Bonetti, M., Benussi, L., Ghidoni, R., & Geroldi, C. (2009). Markers of Alzheimer’s disease in a population attending a memory clinic. *Alzheimer’s and Dementia*, *5*(4). <https://doi.org/10.1016/j.jalz.2009.04.1235>
12. Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., Bessi, V., & Nacmias, B. (2022). Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment. *Journal of Neurology*, *269*(8). <https://doi.org/10.1007/s00415-022-11055-5>
13. Gibbons, G. S., Kim, S. J., Robinson, J. L., Changolkar, L., Irwin, D. J., Shaw, L. M., Lee, V. M. Y., & Trojanowski, J. Q. (2019). Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). *Acta Neuropathologica Communications*, *7*(1). <https://doi.org/10.1186/s40478-019-0687-5>
14. Hampel, H., Mitchell, A., Blennow, K., Frank, R. A., Brettschneider, S., Weller, L., & Möller, H. J. (2004). Core biological marker candidates of Alzheimer’s disease - Perspectives for diagnosis, prediction of outcome and reflection of biological activity. In *Journal of Neural Transmission* (Vol. 111, Issue 3). <https://doi.org/10.1007/s00702-003-0065-z>
15. Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., Shaw, C. E., Foy, C., Poppe, M., Archer, N., Hamilton, G., Powell, J., Brown, R. G., Sham, P., Ward, M., & Lovestone, S. (2006). Proteome-based plasma biomarkers for Alzheimer’s disease. *Brain*, *129*(11). <https://doi.org/10.1093/brain/awl279>
16. Jiang, Y. H., Jhang, J. F., Ho, H. C., Hsu, Y. H., & Kuo, H. C. (2022). Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding. *Scientific Reports*, *12*(1). <https://doi.org/10.1038/s41598-022-10696-w>
17. Jin, J., Guang, M., Ogbuehi, A. C., Li, S., Zhang, K., Ma, Y., Acharya, A., Guo, B., Peng, Z., Liu, X., Deng, Y., Fang, Z., Zhu, X., Hua, S., Li, C., Haak, R., Ziebolz, D., Schmalz, G., Liu, L., … Huang, X. (2021). Shared molecular mechanisms between alzheimer’s disease and periodontitis revealed by transcriptomic analysis. *BioMed Research International*, *2021*. <https://doi.org/10.1155/2021/6633563>
18. Jin, M., Cao, L., & Dai, Y. P. (2019). Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer’s Disease: A Correlative Meta-Analysis. In *Frontiers in Aging Neuroscience* (Vol. 11). <https://doi.org/10.3389/fnagi.2019.00254>
19. Kivisäkk, P., Carlyle, B. C., Sweeney, T., Trombetta, B. A., LaCasse, K., El-Mufti, L., Tuncali, I., Chibnik, L. B., Das, S., Scherzer, C. R., Johnson, K. A., Dickerson, B. C., Gomez-Isla, T., Blacker, D., Oakley, D. H., Frosch, M. P., Hyman, B. T., Aghvanyan, A., Bathala, P., … Arnold, S. E. (2023). Plasma biomarkers for diagnosis of Alzheimer’s disease and prediction of cognitive decline in individuals with mild cognitive impairment. *Frontiers in Neurology*, *14*. <https://doi.org/10.3389/fneur.2023.1069411>
20. Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022). Advances in the development of new biomarkers for Alzheimer’s disease. In *Translational Neurodegeneration* (Vol. 11, Issue 1). <https://doi.org/10.1186/s40035-022-00296-z>
21. Koyner, J. L., Vaidya, V. S., Bennett, M. R., Ma, Q., Worcester, E., Akhter, S. A., Raman, J., Jeevanandam, V., O’Connor, M. F., Devarajan, P., Bonventre, J. V., & Murray, P. T. (2010). Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. *Clinical Journal of the American Society of Nephrology*, *5*(12). <https://doi.org/10.2215/CJN.00740110>
22. Lee, E. H., Kwon, H. S., Koh, S. H., Choi, S. H., Jin, J. H., Jeong, J. H., Jang, J. W., Park, K. W., Kim, E. J., Kim, H. J., Hong, J. Y., Yoon, S. J., Yoon, B., Kang, J. H., Lee, J. M., Park, H. H., & Ha, J. (2022). Serum neurofilament light chain level as a predictor of cognitive stage transition. *Alzheimer’s Research and Therapy*, *14*(1). <https://doi.org/10.1186/s13195-021-00953-x>
23. Lin, Y. S., Lee, W. J., Wang, S. J., & Fuh, J. L. (2018). Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. *Scientific Reports*, *8*(1). <https://doi.org/10.1038/s41598-018-35766-w>
24. Maes, O. C., Kravitz, S., Mawal, Y., Su, H., Liberman, A., Mehindate, K., Berlin, D., Sahlas, D. J., Chertkow, H. M., Bergman, H., Melmed, C., & Schipper, H. M. (2006). Characterization of α1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. *Neurobiology of Disease*, *24*(1). <https://doi.org/10.1016/j.nbd.2006.06.009>
25. Masters, C. L., & Selkoe, D. J. (2012). Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. In *Cold Spring Harbor Perspectives in Medicine* (Vol. 2, Issue 6). <https://doi.org/10.1101/cshperspect.a006262>
26. Mattsson-Carlgren, N., Grinberg, L. T., Boxer, A., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A., Spina, S., Janelidze, S., Rojas-Martinex, J., Rosen, H., la Joie, R., Lesman-Segev, O., Iaccarino, L., Kollmorgen, G., Ljubenkov, P., Eichenlaub, U., Gorno-Tempini, M. L., Miller, B., … Rabinovici, G. D. (2022). Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. *Neurology*, *98*(11). <https://doi.org/10.1212/WNL.0000000000200040>
27. Mayeux, R., & Stern, Y. (2012). Epidemiology of Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, *2*(8). <https://doi.org/10.1101/cshperspect.a006239>
28. McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., Thompson, R., & Alexander-Lindo, R. (2021). Cerebrospinal fluid biomarkers of alzheimer’s disease: Current evidence and future perspectives. In *Brain Sciences* (Vol. 11, Issue 2). <https://doi.org/10.3390/brainsci11020215>
29. O’Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and alzheimer’s disease. *Annual Review of Neuroscience*, *34*. <https://doi.org/10.1146/annurev-neuro-061010-113613>
30. Öhrfelt, A., Dumurgier, J., Zetterberg, H., Vrillon, A., Ashton, N. J., Kvartsberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2020). Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. *Alzheimer’s Research and Therapy*, *12*(1). <https://doi.org/10.1186/s13195-020-00748-6>
31. Papaliagkas, V., Kalinderi, K., Vareltzis, P., Moraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023). CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease. In *International Journal of Molecular Sciences* (Vol. 24, Issue 10). <https://doi.org/10.3390/ijms24108976>
32. Pekeles, H., Qureshi, H. Y., Paudel, H. K., Schipper, H. M., Gornistky, M., & Chertkow, H. (2019). Development and validation of a salivary tau biomarker in Alzheimer’s disease. *Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring*, *11*. <https://doi.org/10.1016/j.dadm.2018.03.003>
33. Prince, M., Ali, G. C., Guerchet, M., Prina, A. M., Albanese, E., & Wu, Y. T. (2016). Recent global trends in the prevalence and incidence of dementia, and survival with dementia. *Alzheimer’s Research and Therapy*, *8*(1). <https://doi.org/10.1186/s13195-016-0188-8>
34. Pyrgelis, E. S., Boufidou, F., Constantinides, V. C., Papaioannou, M., Papageorgiou, S. G., Stefanis, L., Paraskevas, G. P., & Kapaki, E. (2022). Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review. In *Diagnostics* (Vol. 12, Issue 12). <https://doi.org/10.3390/diagnostics12122976>
35. Sanfilippo, C., Forlenza, O., Zetterberg, H., & Blennow, K. (2016). Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD. *Journal of Neural Transmission*, *123*(12). <https://doi.org/10.1007/s00702-016-1597-3>
36. Seol, W., Kim, H., & Son, I. (2020). Urinary biomarkers for neurodegenerative diseases. In *Experimental Neurobiology* (Vol. 29, Issue 5). <https://doi.org/10.5607/EN20042>
37. Simrén, J., Leuzy, A., Karikari, T. K., Hye, A., Benedet, A. L., Lantero-Rodriguez, J., Mattsson-Carlgren, N., Schöll, M., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Aarsland, D., Hansson, O., Rosa-Neto, P., Westman, E., Blennow, K., … Ashton, N. J. (2021). The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. *Alzheimer’s and Dementia*, *17*(7). <https://doi.org/10.1002/alz.12283>
38. Smirnov, D. S., Ashton, N. J., Blennow, K., Zetterberg, H., Simrén, J., Lantero-Rodriguez, J., Karikari, T. K., Hiniker, A., Rissman, R. A., Salmon, D. P., & Galasko, D. (2022). Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change. *Acta Neuropathologica*, *143*(4). <https://doi.org/10.1007/s00401-022-02408-5>
39. Song, W., Kothari, V., Velly, A. M., Cressatti, M., Liberman, A., Gornitsky, M., & Schipper, H. M. (2018). Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson’s disease. *Movement Disorders*, *33*(4). <https://doi.org/10.1002/mds.27328>
40. Strimbu, K., & Tavel, J. A. (2010). What are biomarkers? In *Current Opinion in HIV and AIDS* (Vol. 5, Issue 6). <https://doi.org/10.1097/COH.0b013e32833ed177>
41. Wang, Y., Wang, Y., Zhu, J., Guan, Y., Xie, F., Cai, X., Deng, J., Wei, Y., He, R., Fang, Z., & Guo, Q. (2022). Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer’s disease. *Frontiers in Aging Neuroscience*, *14*. <https://doi.org/10.3389/fnagi.2022.1046066>
42. Wen, L. Y., Wan, L., Lai, J. N., Chen, C. S., Chen, J. J. Y., Wu, M. Y., Hu, K. C., Chiu, L. T., Tien, P. T., & Lin, H. J. (2021). Increased risk of Alzheimer’s disease among patients with age-related macular degeneration: A nationwide population-based study. *PLoS ONE*, *16*(May). <https://doi.org/10.1371/journal.pone.0250440>
43. Yao, F., Hong, X., Li, S., Zhang, Y., Zhao, Q., Du, W., Wang, Y., & Ni, J. (2018). Urine-Based Biomarkers for Alzheimer’s Disease Identified Through Coupling Computational and Experimental Methods. *Journal of Alzheimer’s Disease : JAD*, *65*(2). <https://doi.org/10.3233/JAD-180261>
44. Zou, K., Abdullah, M., & Michikawa, M. (2020). Current biomarkers for alzheimer’s disease: From csf to blood. In *Journal of Personalized Medicine* (Vol. 10, Issue 3). https://doi.org/10.3390/jpm10030085